Patents by Inventor Volkmar Guenzler-Pukall

Volkmar Guenzler-Pukall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170216274
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erthropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Application
    Filed: April 21, 2017
    Publication date: August 3, 2017
    Inventors: Stephen J. Klaus, Christopher J. Molineaux, Thomas B. Neff, Volkmar Guenzler-Pukall, Robert C. Stephenson, Todd W. Seeley, Ingrid Langsetmo Parobok
  • Publication number: 20170216248
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erthropoiesis and iron metabolism, and far treating or preventing iron deficiency and anemia of chronic disease.
    Type: Application
    Filed: April 13, 2017
    Publication date: August 3, 2017
    Inventors: Stephen J. Klaus, Christopher J. Molineaux, Thomas B. Neff, Volkmar Guenzler-Pukall, Robert C. Stephenson, Todd W. Seeley, Ingrid Langsetmo Parobok
  • Publication number: 20170035747
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Application
    Filed: April 19, 2016
    Publication date: February 9, 2017
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • Patent number: 9339527
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: May 17, 2016
    Assignee: FibroGen, Inc.
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • Publication number: 20150246886
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erythropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Application
    Filed: November 19, 2013
    Publication date: September 3, 2015
    Inventors: Stephen J. Klaus, Christopher J. Molineaux, Thomas B. Neff, Volkmar Guenzler-Pukall, Robert C. Stephenson, Todd W. Seeley, Ingrid Langsetmo Parobok
  • Publication number: 20150080425
    Abstract: The present invention provides methods for treating anemia in a subject having kidney failure by administering a compound that inhibits hypoxia-inducible factor (HIF) prolyl hydroxylase.
    Type: Application
    Filed: July 16, 2014
    Publication date: March 19, 2015
    Applicant: FibroGen, Inc.
    Inventors: STEPHEN J. KLAUS, Al Y. Lin, Thomas B. Neff, Qingjian Wang, Volkmar Guenzler-Pukall, Lee A. Flippin, Michael P. Arend, Alex Melekhov
  • Patent number: 8916585
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: December 23, 2014
    Assignee: Fibrogen, Inc.
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • Publication number: 20140343094
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Application
    Filed: May 21, 2014
    Publication date: November 20, 2014
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • Patent number: 8765956
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: July 1, 2014
    Assignee: Fibrogen, Inc.
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • Publication number: 20140163061
    Abstract: The present invention provides methods and medicaments for reducing blood pressure. Methods and medicaments for treating or preventing hypertension are also provided.
    Type: Application
    Filed: February 14, 2014
    Publication date: June 12, 2014
    Applicant: FibroGen, Inc.
    Inventors: Volkmar Guenzler-Pukall, Qingjian Wang, Ingrid Langsetmo Parobok, Guangjie Guo
  • Publication number: 20140142136
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erythropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Application
    Filed: November 19, 2013
    Publication date: May 22, 2014
    Inventors: Stephen J. Klaus, Christopher J. Molineaux, Thomas B. Neff, Volkmar Guenzler-Pukall, Robert C. Stephenson
  • Patent number: 8629131
    Abstract: The present invention relates to methods for increasing iron absorption in a subject by administering to the subject an effective amount of a compound that inhibits hypoxia-inducible factor prolyl hydroxylase activity.
    Type: Grant
    Filed: July 12, 2010
    Date of Patent: January 14, 2014
    Assignee: Fibrogen, Inc.
    Inventors: Stephen J. Klaus, Christopher J. Molineaux, Thomas B. Neff, Volkmar Guenzler-Pukall, Ingrid Langsetmo Parobok, Todd W. Seeley, Robert C. Stephenson
  • Patent number: 8614204
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erythropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Grant
    Filed: June 3, 2004
    Date of Patent: December 24, 2013
    Assignee: Fibrogen, Inc.
    Inventors: Stephen J. Klaus, Christopher J. Molineaux, Thomas B. Neff, Volkmar Guenzler-Pukall, Ingrid Langsetmo Parobok, Todd W. Seeley, Robert C. Stephenson
  • Patent number: 8609646
    Abstract: The present invention relates to methods and compounds for decreasing the expression of hepcidin, a protein associated with regulation of iron metabolism.
    Type: Grant
    Filed: July 12, 2010
    Date of Patent: December 17, 2013
    Assignee: Fibrogen, Inc.
    Inventors: Stephen J. Klaus, Christopher J. Molineaux, Thomas B. Neff, Volkmar Guenzler-Pukall, Ingrid Langsetmo Parobok, Todd W. Seeley, Robert C. Stephenson
  • Patent number: 8604013
    Abstract: The present invention relates to methods for treating anemia in a subject having a low percent transferrin saturation by administering to the subject an effective amount of a compound that inhibits hypoxia-inducible factor prolyl hydroxylase activity.
    Type: Grant
    Filed: July 12, 2010
    Date of Patent: December 10, 2013
    Assignee: Fibrogen, Inc.
    Inventors: Stephen J. Klaus, Christopher J. Molineaux, Thomas B. Neff, Volkmar Guenzler-Pukall, Ingrid Langsetmo Parobok, Todd W. Seeley, Robert C. Stephenson
  • Patent number: 8604012
    Abstract: The present invention relates to methods and compounds for increasing serum iron in a subject.
    Type: Grant
    Filed: July 12, 2010
    Date of Patent: December 10, 2013
    Assignee: Fibrogen, Inc.
    Inventors: Stephen J. Klaus, Christopher J. Molineaux, Thomas B. Neff, Volkmar Guenzler-Pukall, Ingrid Langsetmo Parobok, Todd W. Seeley, Robert C. Stephenson
  • Publication number: 20130310565
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Application
    Filed: June 7, 2013
    Publication date: November 21, 2013
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • Publication number: 20130245037
    Abstract: The present invention relates to methods of stabilizing the alpha subunit of hypoxia inducible factor (HIF). The invention further relates to methods of preventing, pretreating, or treating conditions associated with HIF, including ischemic and hypoxic conditions. Compounds for use in these methods are also provided.
    Type: Application
    Filed: May 17, 2013
    Publication date: September 19, 2013
    Applicant: FibroGen, Inc.
    Inventors: Volkmar Guenzler-Pukall, Thomas B. Neff, Qingjian Wang, Michael P. Arend, Lee A. Flippin, Alex Melekhov
  • Publication number: 20130203805
    Abstract: The present invention relates to methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. Methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included. Compounds for use in these methods are provided, as are methods of identifying such compounds.
    Type: Application
    Filed: September 13, 2012
    Publication date: August 8, 2013
    Applicant: FIBROGEN, INC.
    Inventors: Stephen J. Klaus, Al Y. Lin, Thomas B. Neff, Qingjian Wang, Volkmar Guenzler-Pukall, Michael P. Arend, Lee A. Flippin, Alex Melekhov
  • Publication number: 20130178417
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Application
    Filed: August 30, 2012
    Publication date: July 11, 2013
    Inventors: Michael P. AREND, Lee A. FLIPPIN, Volkmar GUENZLER-PUKALL, Wen-Bin HO, Eric D. TURTLE, Xiaohui DU